RIFAXIMIN — 200 mg / 400mg / 550 mg tablets
📦 Product Snapshot
Use our inquiry form to request official leaflet links, verify common strengths, and ask general authenticity/packaging questions. We do not provide medical advice.
International visitors: our informational support and inquiry form are available to users in the United States, United Kingdom, and Australia.
🧠 Overview
Rifaximin is a rifamycin antimicrobial agent that is structurally related to rifampin but with a crucial difference: it is designed to be non‑absorbable after oral administration. Less than 0.4% of an orally administered dose is absorbed systemically, meaning the drug remains concentrated within the gastrointestinal lumen where it exerts its antibacterial effects. This unique pharmacokinetic profile makes rifaximin ideal for treating gut‑specific conditions while minimizing systemic side effects.
Mechanism of action: Rifaximin binds irreversibly to the bacterial DNA‑dependent RNA polymerase (rpoB subunit), inhibiting RNA synthesis and leading to bacterial cell death. It has broad‑spectrum bactericidal activity against both Gram‑positive and Gram‑negative aerobic and anaerobic bacteria, including Escherichia coli, and has demonstrated effects against enteric protozoa. Because it reaches high concentrations within the gut lumen, it can effectively modulate gastrointestinal flora without significant systemic exposure.
Approved indications: In the United States and many other countries, rifaximin is FDA‑approved for three specific indications with distinct dosing regimens. For travelers’ diarrhea caused by noninvasive strains of E. coli in adults and children 12 years and older, the dose is 200 mg three times daily for three days. For reduction in risk of overt hepatic encephalopathy recurrence in adults, the dose is 550 mg twice daily, often continued long‑term. For irritable bowel syndrome with diarrhea in adults, the dose is 550 mg three times daily for 14 days, with patients who experience recurrence eligible for up to two additional retreatments.
Off‑label uses: Due to its favorable safety profile and gut‑specific action, rifaximin is widely used off‑label for small intestinal bacterial overgrowth (SIBO), diverticulitis, inflammatory bowel disease (including pouchitis), spontaneous bacterial peritonitis prophylaxis, and Clostridium difficile infection. These uses, while supported by clinical experience and some studies, are not FDA‑approved.
🏷️ Strengths & Brand Examples
- 200 mg tablets (round, pink, debossed Sx) — for travelers’ diarrhea.
- 550 mg tablets (oval, pink, debossed rfx) — for hepatic encephalopathy and IBS-D.
- XIFAXAN® 200 mg and 550 mg tablets (Salix Pharmaceuticals).
- Rixophil® 200 mg film‑coated tablets (Ratnatris Pharmaceuticals Pvt. Ltd.) — registered in Philippines, manufactured in India.
- Rifagut 200mg / 400mg / 550mg (SunPharma)
- Rifaximin 550 mg tablets (Healing Pharma, brand Rifaxiheal®) — available through distributors.
- Rifacol 550 mg tablets (various manufacturers).
- Generic rifaximin available from multiple Indian manufacturers including Sun Pharma, Cipla, Alkem, Zydus, Intas, and Lupin.
⚠️ Safety, Side Effects & Monitoring
- Travelers’ diarrhea (≥2%): Headache (10% vs 9% placebo).
- Hepatic encephalopathy (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), pruritus (10%).
- IBS-D (≥2%): Nausea (3%), ALT increased (2%).
- Other: Muscle spasms, arthralgia, dyspnea, pyrexia, rash, depression, nasopharyngitis, abdominal pain.
• Travelers’ diarrhea not caused by E. coli: Rifaximin was not effective in diarrhea complicated by fever or blood in stool, or diarrhea due to pathogens other than E. coli (e.g., Campylobacter jejuni, Shigella, Salmonella). Discontinue if symptoms worsen or persist more than 24-48 hours and consider alternative antibiotics.
• Clostridium difficile‑associated diarrhea (CDAD): Reported with nearly all antibacterials, including rifaximin, ranging from mild diarrhea to fatal colitis. Consider in all patients presenting with diarrhea after antibiotic use (can occur up to 2 months after treatment). If suspected or confirmed, discontinue antibiotic use not directed against C. difficile.
• Severe hepatic impairment (Child‑Pugh Class C): Systemic exposure is increased in patients with severe hepatic impairment. Clinical trials were limited to patients with MELD scores less than 25. Use with caution; monitor for adverse effects.
• Concomitant P‑glycoprotein inhibitors (e.g., cyclosporine): May substantially increase systemic exposure to rifaximin. Caution when concomitant use is needed, especially in patients with hepatic impairment where additive effects may occur.
• Pregnancy: Based on animal data, rifaximin may cause fetal harm (teratogenic effects observed in rats and rabbits including maxillofacial, cardiac, ocular, and spine malformations). Advise pregnant women of potential risk.
• INR changes with warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed.
- History of hypersensitivity to rifaximin, any rifamycin antimicrobial agent (rifampin, rifabutin), or any component of the formulation.
- Do not use in travelers’ diarrhea with fever or blood in stool, or when non‑E. coli pathogens are suspected.
- P‑glycoprotein inhibitors (cyclosporine, eliglustat): May significantly increase systemic rifaximin exposure. Observe for increased adverse effects if concomitant use necessary.
- Warfarin: INR changes reported. Monitor INR and prothrombin time; adjust warfarin dose as needed.
- CYP3A4 substrates: Although rifaximin is minimally absorbed, theoretical potential for CYP3A4 induction exists with very high exposure; monitor for reduced efficacy of sensitive CYP3A4 substrates.
- Pregnancy: No adequate human data; animal studies show teratogenicity. Use only if clearly needed and benefit outweighs risk. Advise of potential fetal harm.
- Breastfeeding: Due to poor oral absorption, rifaximin is unlikely to reach breastmilk or cause adverse effects in breastfed infants. However, no published experience exists; an alternate drug may be preferred, particularly when nursing a newborn or preterm infant.
- Pediatric use: Travelers’ diarrhea: approved for patients 12 years and older (200 mg three times daily for 3 days). Safety and efficacy for hepatic encephalopathy and IBS-D not established in pediatric patients younger than 18 years.
- Geriatric use: Clinical studies did not include sufficient numbers; no specific problems demonstrated, but elderly may have age‑related hepatic/renal impairment.
- Hepatic impairment: Mild‑moderate: no dose adjustment generally needed. Severe (Child‑Pugh Class C): increased systemic exposure; use with caution, monitor for adverse effects.
- Renal impairment: No dosage adjustment necessary due to minimal absorption; not studied.
- Symptoms: No specific overdose information; expected symptoms would likely be gastrointestinal (nausea, diarrhea) due to local effects.
- Management: Supportive care, monitoring of vital signs, activated charcoal if recent ingestion. No specific antidote.